Saso Dohcev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Saso Dohcev has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Goce Spasovski
Department of Nephrology, University Sts. Cyril and Methodius, 1000 Skopje, North Macedonia
2 shared publications - Aleksandar Trifunovski
Department of Urology, Ss. Cyril and Methodius University in Skopje Faculty of Medicine, Skopje, Republic of North Macedonia
1 shared publication - Aleksandra Gavrilovska-Brzanov
Department of Anesthesiology, Reanimation and Intensive Care Medicine and Emergency, Ss. Cyril and Methodius University in Skopje Faculty of Medicine, Skopje, Republic of North Macedonia
1 shared publication - Dimitar Trajkovski
Department of Urology, Ss. Cyril and Methodius University in Skopje Faculty of Medicine, Skopje, Republic of North Macedonia
1 shared publication Elena Mirceska Arsovska
University Clinic for Dermatology, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Republic of North Macedonia
1 shared publication- Gordana Petrusevska
Institute of Pathology, Faculty of Medicine, Ss. Cyril and Methodius University, 1000 Skopje, North Macedonia
1 shared publication
Latest Publications
- Open Access
- 4 May 2026
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 42 (2) , 251-257
Kidney transplantation in Alport syndrome: A genotype-guided case series and literature review
Kidney transplantation in Alport syndrome: A genotype-guided case series and literature review - Turkish Journal of Surgery
- 4 May 2026
- Published by Galenos Yayinevi in Turkish Journal of Surgery
- Vol. 42 (2) , 251-257
Open AccessKidney transplantation in Alport syndrome: A genotype-guided case series and literature review
Kidney transplantation in Alport syndrome: A genotype-guided case series and literature review - Turkish Journal of Surgery
- Open Access
- 12 June 2025
- Published by University Ss. Cyril and Methodius in Skopje in Academic Medical Journal
- Vol. 5 (1) , 103-118
CHRONIC INFLAMMATION IN DIALYSIS PATIENTS AND ITS CORRELATION WITH DERMATOLOGICAL MANIFESTATIONS: A MULTICENTER STUDY FROM SKOPJE
Introduction: Chronic systemic inflammation is a defining feature in dialysis patients, contributing significantly to dermatological manifestations such as pruritus, xerosis, pigmentation changes, and nail abnormalities. These conditions impair quality of life and are linked to markers of systemic inflammation and dialysis-related factors. Objectives: This study aimed to analyze the prevalence and severity of dermatological manifestations in dialysis patients, and their correlations with systemic inflammation. Methods: An observational, cross-sectional study was conducted in two dialysis centers in Skopje, North Macedonia, involving 167 chronic dialysis patients. Data collection included dermatological assessments, laboratory markers (e.g., CRP, PTH, MPV), and pharmacological histories. Statistical analyses were used to explore correlations. Results: Pruritus was observed in 74% of patients and correlated significantly with CRP (R=0.223, p=0.005) and PTH (R=0.219, p=0.008). Xerosis affected 88.62% of patients, with moderate severity in 38.92%, and correlated with CRP (R=0.215, p=0.003). Pigmentation changes (63.47%) were linked to MPV (R=0.219, p=0.004), while nail abnormalities (81.44%) correlated with ferritin (R=0.170, p=0.028). Conclusion: Dermatological manifestations are prevalent in dialysis patients and closely associated with systemic inflammation markers. A multidisciplinary approach is essential to improve management and patient outcomes.
- 12 June 2025
- Published by University Ss. Cyril and Methodius in Skopje in Academic Medical Journal
- Vol. 5 (1) , 103-118
Open AccessCHRONIC INFLAMMATION IN DIALYSIS PATIENTS AND ITS CORRELATION WITH DERMATOLOGICAL MANIFESTATIONS: A MULTICENTER STUDY FROM SKOPJE
Introduction: Chronic systemic inflammation is a defining feature in dialysis patients, contributing significantly to dermatological manifestations such as pruritus, xerosis, pigmentation changes, and nail abnormalities. These conditions impair quality of life and are linked to markers of systemic inflammation and dialysis-related factors. Objectives: This study aimed to analyze the prevalence and severity of dermatological manifestations in dialysis patients, and their correlations with systemic inflammation. Methods: An observational, cross-sectional study was conducted in two dialysis centers in Skopje, North Macedonia, involving 167 chronic dialysis patients. Data collection included dermatological assessments, laboratory markers (e.g., CRP, PTH, MPV), and pharmacological histories. Statistical analyses were used to explore correlations. Results: Pruritus was observed in 74% of patients and correlated significantly with CRP (R=0.223, p=0.005) and PTH (R=0.219, p=0.008). Xerosis affected 88.62% of patients, with moderate severity in 38.92%, and correlated with CRP (R=0.215, p=0.003). Pigmentation changes (63.47%) were linked to MPV (R=0.219, p=0.004), while nail abnormalities (81.44%) correlated with ferritin (R=0.170, p=0.028). Conclusion: Dermatological manifestations are prevalent in dialysis patients and closely associated with systemic inflammation markers. A multidisciplinary approach is essential to improve management and patient outcomes.
- Open Access
- 1 November 2022
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 48 (6) , 423-430
AHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study
Objective: This study aimed to measure the AHNAK2 urinary levels in bladder cancer patients. Material and methods: This prospective case–control study enrolled 67 participants between January and March 2019 and were categorized into bladder cancer group (n=37), with histologically proven bladder cancer, and control group (n=30), with histologically verified benign lesions or with no bladder cancer indication during follow-up. Urine samples of 15 mL were collected in the mid-morning before cystoscopy/surger y and an enzyme-linked immunosorbent assay was performed as per the manufacturer’s protocol. Bladder malignancies were classified according to the World Health Organization Tumor Classification. Group’s associations were evaluated with the Student t-test, Spearman’s rank correlation, and Mann–Whitney U test, while receiver operating curve was plotted for assessing the test’s performance. Results: Mean age of the bladder cancer group was 66.41 years (standard deviation=10.04, range=43-82 years) and the control group was 59.67 years (standard deviation=10.44, range=38-77 years). All bladder cancers were of the urothelial histotype, with the following pT distribution: pTa/papillary urothelial neoplasm of low malignant potential (n=19; 28.4%), Primary tumor (pT) in situ (n=4; 6%), pT1 (n=7; 10.4%), and pT≥2 (n=7; 10.48%). Mean AHNAK2 levels were higher in bladder cancer patients 49.08 pg/mL (standard deviation=114.91) compared to controls 5.28 pg/mL (standard deviation=6.65), P < .05). Significant differences were noted between non-invasive bladder cancer (n=23; mean=7.14 pg/mL; standard deviation=7.26) and invasive bladder cancer (n=14; mean=117.99 pg/mL; standard deviation=168.08) and between non-muscle invasive bladder cancer (mean=23.19 pg/mL; standard deviation=66.93) and muscle-invasive bladder cancer (mean=160.05 pg/mL; standard deviation=199.65) (P < .001). The result of the assays was given as follows: sensitivity: 64.19%, specificity: 66.67%, positive predictive value: 22.07%, negative predictive value: 92.37%, area under curve: 0.695, and 95% CI: 0.57-0.82. Conclusion: AHNAK2 protein could be used as bladder cancer surveillance biomarker. The inclusion of AHNAK2 levels in stratification nomograms might reduce the number of unnecessary cystoscopies. Cite this article as: Komina S, Petrusevska G, Jovanovic R, et al. AHNAK2 urinary protein expression as potential biomarker for bladder cancer detection: A pilot study. Turk J Urol. 2022;48(6):423-430.
- 1 November 2022
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 48 (6) , 423-430
Open AccessAHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study
Objective: This study aimed to measure the AHNAK2 urinary levels in bladder cancer patients. Material and methods: This prospective case–control study enrolled 67 participants between January and March 2019 and were categorized into bladder cancer group (n=37), with histologically proven bladder cancer, and control group (n=30), with histologically verified benign lesions or with no bladder cancer indication during follow-up. Urine samples of 15 mL were collected in the mid-morning before cystoscopy/surger y and an enzyme-linked immunosorbent assay was performed as per the manufacturer’s protocol. Bladder malignancies were classified according to the World Health Organization Tumor Classification. Group’s associations were evaluated with the Student t-test, Spearman’s rank correlation, and Mann–Whitney U test, while receiver operating curve was plotted for assessing the test’s performance. Results: Mean age of the bladder cancer group was 66.41 years (standard deviation=10.04, range=43-82 years) and the control group was 59.67 years (standard deviation=10.44, range=38-77 years). All bladder cancers were of the urothelial histotype, with the following pT distribution: pTa/papillary urothelial neoplasm of low malignant potential (n=19; 28.4%), Primary tumor (pT) in situ (n=4; 6%), pT1 (n=7; 10.4%), and pT≥2 (n=7; 10.48%). Mean AHNAK2 levels were higher in bladder cancer patients 49.08 pg/mL (standard deviation=114.91) compared to controls 5.28 pg/mL (standard deviation=6.65), P < .05). Significant differences were noted between non-invasive bladder cancer (n=23; mean=7.14 pg/mL; standard deviation=7.26) and invasive bladder cancer (n=14; mean=117.99 pg/mL; standard deviation=168.08) and between non-muscle invasive bladder cancer (mean=23.19 pg/mL; standard deviation=66.93) and muscle-invasive bladder cancer (mean=160.05 pg/mL; standard deviation=199.65) (P < .001). The result of the assays was given as follows: sensitivity: 64.19%, specificity: 66.67%, positive predictive value: 22.07%, negative predictive value: 92.37%, area under curve: 0.695, and 95% CI: 0.57-0.82. Conclusion: AHNAK2 protein could be used as bladder cancer surveillance biomarker. The inclusion of AHNAK2 levels in stratification nomograms might reduce the number of unnecessary cystoscopies. Cite this article as: Komina S, Petrusevska G, Jovanovic R, et al. AHNAK2 urinary protein expression as potential biomarker for bladder cancer detection: A pilot study. Turk J Urol. 2022;48(6):423-430.